Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Myc inhibitor OMO-103

A peptide inhibitor of the proto-oncogene Myc, with potential antineoplastic activity. Upon administration, Myc inhibitor OMO-103 enters cells, reaches the nucleus and inhibits Myc. This may inhibit tumor cell growth and proliferation. Myc, a proto-oncogene dysregulated in a variety of cancers, plays a role in the regulation of transcription and cell proliferation.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	OMO 103 OMO-103 OMO103

Myc inhibitor OMO-103

Search NCI's Drug Dictionary